15-min delayed · Aug 24, 8:00 AM ET · Get real-time quotes →
The Quantellect read.Of the 18 firms covering Apellis Pharmaceuticals Inc, 5 rate it Buy or better, 12 sit at Hold, and 1 rate it Sell or worse, a moderate buy consensus. Targets range widely, $18.00 to $52.00 (about 2.9x), a sign of real disagreement on valuation. The average target of $35.38 sits 972% above the current $3.30. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near -8% this year and 11% next, consensus EPS building from about $-0.26 next quarter toward $-0.22 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS18 ratings
Moderate Buy
Strong Buy00%
Buy528%
Hold1267%
Sell16%
Strong Sell00%
Based on 18 analysts giving stock ratings to Apellis Pharmaceuticals Inc.
As of Aug, 5 of 18 firms rate APLS a Buy (12 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
APLS EPS & revenue forecast
EPS · NEXT QUARTER
$-0.26
Range $-0.60 – $-0.10 · 12 analysts · -116% YoY
Next period, 12 analysts expect Apellis Pharmaceuticals Inc to earn $-0.26 a share (range $-0.60 – $-0.10), versus $1.67 a year earlier. Full-year consensus is $-1.13, growing to $-0.22 the year after.
REVENUE · NEXT QUARTER
$218.7M
Range $207.2M – $233.5M · 12 analysts · -52% YoY
Revenue is expected to reach $218.7M (range $207.2M – $233.5M), -52.0% year-over-year. Full-year consensus is $925.4M, rising to $1.0B next year.
Top analysts covering Apellis Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on APLS.
#1
Luca Issi
RBC Capital · Rank #1
Hold
$18.00+445.5% to target
Overall win rate
55%
+ Follow
#2
Laura Chico
Wedbush · Rank #70
Hold
$18.00+445.5% to target
Overall win rate
44%
+ Follow
#3
Anupam Rama
JP Morgan · Rank #79
Hold
$41.00+1142.4% to target
Overall win rate
50%
+ Follow
#4
Greg Harrison
Scotiabank · Rank #178
Hold
$22.00+566.7% to target
Overall win rate
38%
+ Follow
#5
Joseph Stringer
Needham · Rank #192
Hold
No targeton APLS
Overall win rate
36%
+ Follow
APLS stock forecast FAQ
What is APLS's average 12-month price target?+
The 14 analysts with a live target average $35.38 for Apellis Pharmaceuticals Inc over the next 12 months, ranging from a $52.00 high to a $18.00 low.
Is APLS stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 18 analyst ratings, 5 are Buy or Strong Buy, 12 are Hold, and 1 are Sell or Strong Sell.
What are the highest and lowest price targets for APLS?+
The Street-high target is $52.00 (Baird), and the Street-low is $18.00 (Wedbush). The average of all 14 active targets is $35.38.
How many Wall Street analysts cover APLS?+
18 analysts have an active rating on Apellis Pharmaceuticals Inc, and 14 firms carry a live 12-month price target.
Who is the most accurate analyst covering APLS?+
Among analysts who currently cover APLS, Luca Issi of RBC Capital has the strongest overall Quantellect track record (Rank #1). Their current call is Hold with a $18.00 target.
What is Apellis Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.26 per share (range $-0.60 – $-0.10) across 12 analysts. Full-year EPS is projected at $-1.13, rising to $-0.22 the following year.
How much revenue is Apellis Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $218.7M (range $207.2M – $233.5M). Full-year revenue is projected at $925.4M, growing to $1.0B next year.
Have analysts been upgrading or downgrading APLS lately?+
As of Aug, 5 of 18 firms rate APLS a Buy (12 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their APLS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
